GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Net Cash per Share

Shanghai Henlius Biotech (HKSE:02696) Net Cash per Share : HK$-13.38 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Shanghai Henlius Biotech's Net Cash per Share for the quarter that ended in Dec. 2024 was HK$-13.38.

The historical rank and industry rank for Shanghai Henlius Biotech's Net Cash per Share or its related term are showing as below:

During the past 8 years, the highest Price-to-Net-Cash Ratio of Shanghai Henlius Biotech was 49.70. The lowest was 49.70. And the median was 49.70.

HKSE:02696's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 3.86
* Ranked among companies with meaningful Price-to-Net-Cash only.

Shanghai Henlius Biotech Net Cash per Share Historical Data

The historical data trend for Shanghai Henlius Biotech's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Net Cash per Share Chart

Shanghai Henlius Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Cash per Share
Get a 7-Day Free Trial -4.64 -10.64 -13.58 -13.53 -13.38

Shanghai Henlius Biotech Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.58 -13.92 -13.53 -13.37 -13.38

Competitive Comparison of Shanghai Henlius Biotech's Net Cash per Share

For the Biotechnology subindustry, Shanghai Henlius Biotech's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Henlius Biotech's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Shanghai Henlius Biotech's Price-to-Net-Cash falls into.


;
;

Shanghai Henlius Biotech Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Shanghai Henlius Biotech's Net Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as

Net Cash per Share (A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(825.27-8097.117-0)/543.495
=-13.38

Shanghai Henlius Biotech's Net Cash per Share for the quarter that ended in Dec. 2024 is calculated as

Net Cash per Share (Q: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(825.27-8097.117-0)/543.495
=-13.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Henlius Biotech  (HKSE:02696) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Shanghai Henlius Biotech Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Henlius Biotech Business Description

Traded in Other Exchanges
N/A
Address
B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Executives
Ubs Group Ag
Golden Valley Value Select Master Fund 2101 Beneficial owner
Vistra Trust (singapore) Pte. Limited 2301 Trustee
Lvc Sg Management Pte. Ltd. 2201 Interest of corporation controlled by you
Lvc Management Holdings Limited 2201 Interest of corporation controlled by you
Lin Lijun 2201 Interest of corporation controlled by you
Qatar Investment Authority 2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 2201 Interest of corporation controlled by you
Guo Guangchang 2201 Interest of corporation controlled by you
Fosun International Limited 2201 Interest of corporation controlled by you
Fosun International Holdings Ltd. 2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited 2101 Beneficial owner
Fosun Holdings Limited 2201 Interest of corporation controlled by you
Liu Scott Shi-kau 2201 Interest of corporation controlled by you

Shanghai Henlius Biotech Headlines

No Headlines